Search Results 371-380 of 19204 for Hemoglobin

  1. Neurology - Clinical trials

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

  2. Neurology - Clinical trials - Mayo Clinic

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

  3. Oncology (Medical) - Clinical trials

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

  4. Imatinib (oral route) - Side effects & dosage - Mayo Clinic

    Aggressive systemic mastocytosis (ASM); Chronic eosinophilic leukemia (CEL); Dermatofibrosarcoma protuberans (DFSP); Gastrointestinal stromal tumors (GIST) ...

  5. HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis - Mayo Clinic

    corrected for hemoglobin > 50% and forced expiratory volume in first second (FEV1) predicted > 50% based on most recent pulmonary function test (PFT) ...

  6. Neurology - Clinical trials

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

  7. Clinical trials - Oncology (Medical)

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

  8. A Study to Evaluate Pembrolizumab for Surgically Treated Adjuvant Merkel Cell Carcinoma - Mayo Clinic

    Hemoglobin ≥ 8 g/dL (≥ 80 g/L; may be transfused):. Hemoglobin: __________Date Obtained: ______. Creatinine ≤ 2.0 x ULN: Creatinine: ______ ...

  9. Bendamustine Hydrochloride and Rituximab with or without Bortezomib Followed by Rituximab with or without Lenalidomide in Treating Patients with High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma - Mayo Clinic

    Hemoglobin level < 12 g/dL; > 4 nodal areas; Serum LDH level above normal. At least 1 objective measurable disease parameter. Baseline measurements and ...

  10. To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis - Mayo Clinic

    Unwillingness to receive RBC transfusions to treat low hemoglobin levels. ... Receipt of any live vaccine within 30 days of the first dose of study drug.